開発・製造受託機関アウトソーシング市場規模、シェア、成長分析、CMO別、CRO別、地域別-産業別予測、2025～2032年

世界の開発・製造受託機関（CDMO）アウトソーシング市場規模は、2023年に2,286億3,000万米ドルと評価され、2024年の2,432億6,000万米ドルから2032年には3,995億8,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.4%で成長する展望です。

世界の開発・製造受託機関アウトソーシング市場は、革新的な治療に対する需要の高まりと新薬の複雑化により、大きな成長を遂げています。製薬企業は大小を問わず、医薬品開発プロセスを合理化するためにCDMOと戦略的に提携し、専門的な社内施設を不要にしています。CDMOは、医薬品研究や前臨床検査から原薬（API）や最終製品の製造まで、バリューチェーン全体を網羅する包括的なサービスを提供しています。多くの小規模製薬企業が社内に製造能力を持たないため、この動向は加速すると予想されます。その結果、効率的でタイムリーな医薬品開発と商業化を実現するために、CDMOとのパートナーシップはますます不可欠なものとなると考えられます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客と購買基準の分析

世界の開発・製造受託機関アウトソーシング市場規模：CMO別 & CAGR（2025～2032年）

• 市場概要
• API製造
• 完成品製造
  • 固形剤形
  • 注射剤
  • その他
• 包装
• その他

世界の開発・製造受託機関アウトソーシング市場規模：CRO別 & CAGR（2025～2032年）

• 市場概要
• 初期段階の開発サービス
  • 化学製造管理（CMC）
  • 前臨床サービス
  • 発見
• 臨床
  • フェーズ1
  • フェーズ2
  • フェーズ3
  • フェーズ4
• ラボサービス
• その他

世界の開発・製造受託機関アウトソーシング市場規模&CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主要市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
• 製品ポートフォリオ分析
• セグメント別シェア分析
• 収益の前年比比較（2022～2024年）

  主要企業プロファイル

  • Lonza Group（スイス）
  • Catalent（米国）
  • WuXi Biologics（中国）
  • Samsung Biologics（韓国）
  • Siegfried Holding AG（スイス）
  • Fujifilm Diosynth BIoTechnologies（日本）
  • Recipharm AB（スウェーデン）
  • Boehringer Ingelheim（ドイツ）
  • MilliporeSigma（米国）
  • Aenova Group（ドイツ）
  • Fareva（フランス）
  • Laurus Labs（インド）
  • Delpharm（フランス）
  • Piramal Pharma Solutions（インド）
  • Almac Group（英国）
  • Evonik Industries（ドイツ）
  • Cambrex Corporation（米国）
  • Lonza Group（スイス）
  • Patheon（米国）
  • WuXi AppTec（中国）

結論と推奨事項

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market size was valued at USD 228.63 billion in 2023 and is poised to grow from USD 243.26 billion in 2024 to USD 399.58 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The global contract development and manufacturing organization (CDMO) market is experiencing significant growth, driven by the rising demand for innovative therapeutics and the increasing complexity of new medicines. Pharmaceutical companies, both large and small, are strategically partnering with CDMOs to streamline their drug development processes, eliminating the need for specialized in-house facilities. CDMOs offer a comprehensive range of services that encompass the entire value chain, from drug research and preclinical trials to manufacturing active pharmaceutical ingredients (API) and finished products. This trend is expected to accelerate as many small pharmaceutical firms lack internal manufacturing capabilities. As a result, CDMO partnerships are set to become increasingly vital in ensuring efficient and timely drug development and commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market Segmental Analysis

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market is segmented by CMO, CRO and region. Based on CMO, the market is segmented into API Manufacturing, Finished Product Manufacturing, Packaging and Others. Based on CRO, the market is segmented into Early Phase Development Services, Clinical, Laboratory Service and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market

The global Contract Development and Manufacturing Organization (CDMO) outsourcing market is driven by the increased prevalence of chronic diseases driven by factors such as a growing westernized lifestyle, economic growth, and rising populations. Over 133 million Americans are affected by chronic conditions, representing over 40% of the population, and projections indicate that worldwide figures may reach 157 million by 2020. The market is further bolstered by significant investments from CDMOs looking to innovate and expand geographically, as seen in AbbVie's new API facility in Singapore. Additionally, partnerships between emerging companies like Cugene Inc. and established firms are facilitating market growth, particularly in innovative treatments for autoimmune and inflammatory diseases.

Restraints in the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market

The growth of the Global Contract Development and Manufacturing Organization (CDMO) outsourcing market is likely to be hindered by several key factors. Stringent government regulations and a decrease in the approval rates for various small molecules and biologics in developed regions play a significant role in this restraint. Furthermore, smaller-scale CDMOs that lack advanced equipment are at a higher risk of encountering process errors, compromising quality, and experiencing escalating costs. These issues collectively pose challenges that may adversely impact the overall expansion of the CDMO market during the forecast period, complicating operations and reducing competitiveness.

Market Trends of the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market

The global Contract Development and Manufacturing Organization (CDMO) outsourcing market is witnessing significant fragmentation driven by the rising demand for rapid innovations and efficient process solutions in drug development. As pharmaceutical companies seek to streamline operations and enhance productivity, CDMOs are increasingly partnering with both small and large pharmaceutical and biotech enterprises, as well as life sciences corporations. This trend not only bolsters their service offerings but also fosters collaboration and knowledge-sharing, ultimately leading to improved operational efficiencies and accelerated time-to-market for new therapeutics. This dynamic environment is characterized by strategic alliances, technological advancements, and a focus on customized solutions to meet diverse client needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer & Buying Criteria Analysis

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by CMO & CAGR (2025-2032)

• Market Overview
• API Manufacturing
• Finished Product Manufacturing
  • Solid Dosage Forms
  • Injectables
  • Others
• Packaging
• Others

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by CRO & CAGR (2025-2032)

• Market Overview
• Early Phase Development Services
  • Chemistry, Manufacturing and Controls (CMC)
  • Preclinical Service
  • Discovery
• Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
• Laboratory Service
• Others

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size & CAGR (2025-2032)

• North America (CMO, CRO)
  • US
  • Canada
• Europe (CMO, CRO)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (CMO, CRO)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (CMO, CRO)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (CMO, CRO)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aenova Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fareva (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laurus Labs (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delpharm (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Pharma Solutions (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik Industries (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Patheon (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations